Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment
Sara Serra(Italian institute for Genomic Medicine), Silvia Deaglio(Department of Medical Sciences), Richard R. Furman(Cornell University), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Tiziana Vaisitti(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Marta Coscia(University of Turin), Nicholas Chiorazzi(Feinstein Institute for Medical Research), Simon C. Robson(Beth Israel Deaconess Medical Center), Valentina Audrito(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Shih‐Shih Chen(Feinstein Institute for Medical Research), Cinzia Bologna(Italian institute for Genomic Medicine), Francesca Arruga(Italian institute for Genomic Medicine), Davide Brusa(Italian institute for Genomic Medicine), Roberta Buonincontri(Italian institute for Genomic Medicine), Ozren Jakšić(University of Zagreb), Giorgio Inghirami(Cornell University)
Cited by 57
Related Papers
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
|The Journal of Experimental Medicine|2007|2.4k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k